WO2015114194A1 - Composition de soufre liposomé - Google Patents

Composition de soufre liposomé Download PDF

Info

Publication number
WO2015114194A1
WO2015114194A1 PCT/ES2015/070062 ES2015070062W WO2015114194A1 WO 2015114194 A1 WO2015114194 A1 WO 2015114194A1 ES 2015070062 W ES2015070062 W ES 2015070062W WO 2015114194 A1 WO2015114194 A1 WO 2015114194A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
composition
phospholipids
acid
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2015/070062
Other languages
English (en)
Spanish (es)
Inventor
Pedro González Enseñat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENOC SOLUTIONS S L
Original Assignee
ENOC SOLUTIONS S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENOC SOLUTIONS S L filed Critical ENOC SOLUTIONS S L
Publication of WO2015114194A1 publication Critical patent/WO2015114194A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a composition of liposomes containing sulfur element incorporated into its lipid membrane and the use of said composition in the treatment of diseases, mainly dermatological, such as seborrheic dermatitis or acne, in addition to others. . Therefore, the invention could be framed in the field of pharmacology and cosmetics.
  • the topical applications of the element sulfur in different forms or galenic preparations are multiple. Due to its keratolytic effect, it is useful in the treatment and prevention of seborrheic dermatitis, acne, rosacea, pityriasis versicolor, some parasitosis such as scabiosis, folliculitis and other skin diseases such as some superficial dermatophytosis, perioral dermatitis, necrotic acne, and certain forms of eczema and psoriasis.
  • the element sulfur has been used in the treatment of some intestinal parasitosis, also as a trace element because of its "nutritive" character essential for the synthesis of many amino acids, for hair loss, strengthening nails, etc.
  • the galenic problem of the element sulfur and other forms thereof includes in many cases the need to use certain components as solvents or dispersants, such as fats or oils, for their final formulation, with an occlusive and greasing effect, the application of which may be counterproductive.
  • solvents or dispersants such as fats or oils
  • the therapeutic sulfur is currently applied to the skin and legs in very different forms or galenic preparations, such as ointments, creams, gels, lotions or milks, soaps or shampoos, masks and ointments.
  • the resulting product in its liposomal form, is organoleptically much better, easier to apply and tolerable or pleasing to patients, both for its smell and its possible textures and for its ease of application or use, all in comparison with the conventional or conventional forms thereof.
  • concentrations of element sulfur used in conventional forms are high, between 20 and 200 mg / g, in the liposomal form they range between 0.02 and 0.4 mg / ml.
  • the final product a water-based liposomal suspension
  • a water-based liposomal suspension is very easy and quick to apply, such as atomization, rapid absorption and has no occlusive or greasing effect on the treated area. It can be easily applied to faneras, hairs and nails, with the same advantages. Just stains the skin or clothes.
  • the efficacy of the element sulfur in the treatment or prevention of certain pathologies is enhanced, not only by the galenic, pharmacokinetic and pharmacodynamic contributions of the liposomal structure, but also by the recognized anti-seborrheic-anticomedogenic activity of phosphatidylcholine in particular, and unsaturated phospholipids in general, main components of the liposomal membrane, and that act synergistically with sulfur in these pathologies.
  • the antiseborrheic-anticomedogenic efficacy of these compounds is mainly attributed to their high content of linoleic acid.
  • the liposome when solubilizing, suspending or dispersing the element sulfur in an aqueous phase in the form of tiny and very homogeneous particles offers a very good galenic alternative to said active ingredient.
  • the liposome due to its special physicochemical characteristics improves the therapeutic properties of the element sulfur compared to the classical or conventional galenic forms. This improvement is due to the special pharmacodynamic and pharmacokinetic characteristics of the sulfur element encapsulated in the liposomes.
  • compositions that incorporate the liposomal form of sulfur element have better organoleptic characteristics, especially odor, compared to those that contain it in their concentrations and conventional galenic forms.
  • the liposomal formulation of sulfur element allows it to be incorporated and presented in many galenic forms, both in fluid form, lotion, suspension, serum, atomizer, ... as well as in semi-solid forms such as gels, emulsions , emulgeles, ointments, masks, etc.
  • the liposomal "concentrate" or the liposomes with sulfur element is / are easily incorporated / so associable / s to other formulations or products that in addition to it contain other or other synergistic or complementary assets intended for the treatment of different pathologies in order to improve their effectiveness and / or tolerance.
  • the galenic, pharmacokinetic and pharmacodynamic improvements provided by the liposomes of the invention in general, because of its great biocompatibility can be administered by any route improving and enhancing the effects of the element sulfur, allow us to think about new applications of the same by any route of administration and for pathologies not currently contemplated as capable of being treated with sulfur element.
  • the increase in bactericidal capacity of liposomes containing element sulfur, compared to element sulfur in its conventional form, means an improvement in its activity and has the advantage of reinforcing the antiacneic, anti-medogenic, anti-rosacea effect, etc. of the product.
  • the preparation has characteristics, particle size, which allow it to be sterilized both in its concentrate phase and also in its diluted form, as a finished product. This possibility implies the advantage of allowing the products to be packaged and administered without the need to add preservatives to the formulation.
  • a first aspect of the present invention relates to a composition comprising an aqueous phase liposome suspension characterized in that it comprises:
  • Phospholipids with a phosphatidylcholine ratio between 75 and 99.5% by weight Phospholipids with a phosphatidylcholine ratio between 75 and 99.5% by weight
  • liposomes contain sulfur element incorporated into the phospholipid bilayer.
  • the phospholipids of the composition may come from natural lecithins extracted or be of synthetic origin.
  • liposome means a spherical vesicle with at least one membrane composed of a double layer of phospholipids, also called phospholipid bilayer, which consist of hydrophilic and lipophilic parts.
  • the liposomes can be single, oligo- or multilamellar, that is, they can comprise one or more double layers of phospholipids. Although those of the invention, the most suitable and preferred for topical application are unilamellar.
  • composition comprising liposomes
  • compositions that give rise to the formation of liposomes, whether uni-, oligo- or multilamellar and micellar solutions convertible by dilution in liposomes, although preferably unilamellar liposomes are of interest.
  • sulfur element incorporated into the bilayer means that sulfur is part or is included in the lipid bilayer structure of the liposome.
  • the combination of the components of the liposome and the sulfur element as an active principle takes place during their preparation and prior to the manufacture of the liposomal suspension.
  • sulfur element means any form of mineral sulfur with a minimum of 99.5% purity, although preferably the substance known as "flower sulfur” is used which, having an adequate grain size and characteristics and therapeutic and pharmaceutically recognized properties, it becomes the active of said liposomal formulation or preparation.
  • the element sulfur liposomes are first produced or manufactured in a concentrated form that can be stored for long periods of time, and / or, secondly, be diluted or incorporated into another formulation at a certain concentration for application.
  • the product can be applied in the concentrated form of the product, although it must be done very carefully.
  • the composition is presented or prepared in the form of an aqueous suspension at a concentration of sulfur element in liposomal form appropriate or suitable for direct topical application in the form of lotion, atomized or with eyedropper, associated or not with other components or assets.
  • composition is presented in a form suitable for topical, oral, intravenous, intramuscular, intraperitoneal, subcutaneous, cutaneous, nail, capillary or inhalation topical administration.
  • topical cutaneous, nail and capillary route skin and pimples.
  • the liposomes have an average diameter between 40 nm and 500 nm, preferably between 60 nm and 180 nm, and more preferably between 75 nm and 145 nm.
  • the sulfur element incorporated in the liposomes is pharmaceutical grade sulfur flower.
  • the concentration of this element is between 0.004 gr per liter to 0.4 gr per liter, more preferably between 0.012 gr per liter and 0.25 gr per liter, and even more preferably between 0.02 gr per liter and 0.12 gr per liter.
  • the sulfur is preferably at a concentration of 0.4% and in the final product for the patient the preferred concentration is 0.04%.
  • the phospholipid concentration is from 10 g to 200 g per liter of composition, more preferably between 50 g and 150 g per liter of composition and even more preferably between 90 g and 10 g per liter of composition.
  • the phospholipid concentration is preferably 100 g / liter and in the final product is 10 g / liter.
  • the phospholipids have the formula (I):
  • R- ⁇ and R 2 may be the same or different from each other, they are C12-C22 hydrocarbon chains, comprising between 0 and 8 cis double bonds, preferably between 0 and 6 cis double bonds.
  • R- ⁇ and R 2 are selected from the list comprising oleic acid, linoleic acid, linolenic acid, palmitic acid, stearic acid, arachidonic acid eicosapentaenoic acid and docosahexaenoic acid, preferably oleic acid, linoleic acid, acid linolenic, palmitic acid, stearic acid.
  • phospholipids comprising these fatty acids are soy lecithin, egg lecithin, lecithin from other seeds such as pumpkin, etc. and lecithin with omega 3 phospholipids of different origin, krill phospholipids, crustacean phospholipids, seal, etc.
  • the phospholipid has the following fatty acid composition: Fatty acid in R1 and / or R2% in oleic acid phospholipid 6-13
  • the phospholipid has the following fatty acid composition:
  • the phospholipid is selected from the group comprising soy lecithin, egg lecithin, pumpkin seed lecithin, krill lecithin and any of its mixtures, more preferably soy lecithin, although it can also be from egg or other source with high content in phosphatidylcholine.
  • the minimum phosphatidylcholine content of the lecithins or phospholipids necessary for the manufacture or production of the liposomes of the invention is between 75% and 99.5% of the total lipid, more preferably between 96.5 and 98.5% of total lipid.
  • the phospholipid bilayer of the liposome can be composed, in a proportion less than or equal to 25%, of phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, or any of its mixtures and / or degradation products such as lysophosphatidylcholine.
  • the bile salt is selected from the group comprising sodium colalate, sodium deoxycholate, sodium glycocholate, sodium taurocholate, sodium taurodeoxycholate, sodium ursocholate and sodium chenoxycholate, more preferably sodium cholate.
  • the molar ratio of phospholipids / bile salt is between 1, 5 and 10, preferably between 2.5 and 5, and more preferably between 3 and 4.
  • the composition further comprises an alcohol selected from the list comprising ethanol, propanol, isopropanol and any of its mixtures, preferably 96% pharmaceutical grade ethanol.
  • the ratio of alcohol / phospholipid or lecithin in volume / weight is between 0.25 and 3, preferably between 0.75 and 2.5, and more preferably between 1 and 2.
  • the aqueous phase comprises pure water or water with a salt selected from the list comprising sodium chloride, potassium chloride, magnesium chloride, sodium iodide and any mixture thereof, preferably sodium chloride.
  • the salt concentration is less than 9 grams per liter, more preferably between 0 and 0.9 grams per liter.
  • the aqueous phase comprises pure pharmaceutical quality water.
  • the composition further comprises glycated serum, or other sugars such as mannitol.
  • the liposome composition may also contain or comprise excipients.
  • excipient refers to a substance that aids in the administration (absorption) of any of the components of the product of the invention, stabilizes said components or aids in the preparation of the pharmaceutical composition in the sense of giving it consistency and thus stabilizing the suspension, or provide odors that make it more pleasant.
  • excipients may have the function of maintaining joined components such as starches, sugars or cellulose, smell or deodorize function, color function, drug protection function.
  • excipient is defined as that matter that, included in the galenic forms, is added to the active ingredients or to their associations to help their administration, penetration into the skin or pimples, enable their preparation or formulation and stabilize it , modify its organoleptic properties or determine the physicochemical properties of the pharmaceutical composition and its bioavailability.
  • the "pharmaceutically acceptable" excipient must allow the activity of the compounds of the pharmaceutical composition, that is, to be compatible with said components. Examples of excipients are binders, fillers, disintegrators, lubricants, flavorings or flavors and dyes.
  • compositions of the invention may also comprise various antioxidants, such as vitamin E, vitamin A and vitamin C, which would primarily provide a chemical stabilizing effect of the composition, and may also contain perfumes or deodorizing substances.
  • the composition may also contain one or more additives such as buffers, surfactants, thickening agents, preservatives, or any of their mixtures.
  • composition may also contain one or more synergistic or complementary actives of the element sulfur action such as, for example, antibacterials, antiseptics, hair growths, astringent, keratolytic, exfoliants, oxidoreductive assets, etc.
  • synergistic or complementary actives of the element sulfur action such as, for example, antibacterials, antiseptics, hair growths, astringent, keratolytic, exfoliants, oxidoreductive assets, etc.
  • Another aspect of the present invention relates to the use of the composition of the invention for the manufacture of a medicament or a cosmetic or a dietary or a nutraceutical.
  • composition of the invention for the manufacture of a medicament for the topical treatment and / or prevention of a disease that is selected from seborrheic dermatitis, acne, rosacea, pityriasis versicolor, dermatophytosis. superficial, scabiosis, perioral dermatitis, warts, folliculitis, psoriasis, eczema, pruritus, pigmentation problems or spots on the skin, and keratosis.
  • Another aspect of the invention relates to a method of treatment and / or prevention of a disease that is selected from seborrheic dermatitis, acne, rosacea, pityriasis versicolor, superficial dermatophytosis, scabiosis, perioral dermatitis, warts, folliculitis, psoriasis, eczema, pruritus, pigmentation problems or spots on the skin, or keratosis, which comprises the administration of the composition of the invention, preferably topically, to a patient in need.
  • a disease that is selected from seborrheic dermatitis, acne, rosacea, pityriasis versicolor, superficial dermatophytosis, scabiosis, perioral dermatitis, warts, folliculitis, psoriasis, eczema, pruritus, pigmentation problems or spots on the skin, or kera
  • Another aspect of the invention relates to a process for obtaining the composition of the invention comprising the following steps:
  • step (b) dilute by simple agitation the sulfur flower, sulfur element, in said lipid-alcohol mixture of step (b),
  • steps (a) and (c) jointly homogenize the solutions obtained in steps (a) and (c); Said homogenization can be carried out by different mechanical means, stirring, shearing, extrusion, etc. or a mixture of them.
  • step (d) optionally performing a filtering stage of the product obtained in step (d), preferably sterilized, that is, filtering with simultaneous sterilization, f) diluting the liposomal concentrate with sulfur element, obtained following steps a) through e), in water without or with preservative, such as 0.5% phenoxyethanol, until the preparation or formulation has the desired concentration of sulfur element in liposomal form.
  • a filtering stage of the product obtained in step (d) preferably sterilized, that is, filtering with simultaneous sterilization
  • f) diluting the liposomal concentrate with sulfur element obtained following steps a) through e), in water without or with preservative, such as 0.5% phenoxyethanol, until the preparation or formulation has the desired concentration of sulfur element in liposomal form.
  • the product can be used in concentrated form.
  • the product in its concentrated form obtained in steps (d) or (g) can be packaged and stored for later use mixed with other components.
  • compositions of the invention as an active principle in the treatment of different dermatological disorders, both human and veterinary.
  • These particles may or may not be diluted to the desired concentration of administration, for example in a 1/10 ratio to a sulfur concentration of 0.04 mg / ml.
  • the preparation can be sterilized by 0.45 or 0.2 microns also in its diluted form. This possibility allows you to manage the products without adding preservatives.
  • To this final preparation can be added or not preservative, odorizing substances ... This preparation is preferably carried out under vacuum or inert atmosphere to avoid degradation of the different components.
  • composition of the final product had the following composition, presentation and dosage. Composition of the final product:
  • the sufficient amount of product was applied with the atomizer to moisten the area to be treated and perform a light massage to distribute it and make it penetrate better.
  • a daily application was performed, preferably at night. In some cases, the application was repeated, spacing them in time approximately 12 hours, for example, apply in the morning and at night.
  • the final research product was tested in eight adult volunteers, between 48 and 76 years of age, affected by seborrheic dermatitis with an important inflammatory and scaling component, mainly in the nasogenian groove area and front.
  • the clinical trial of the final research product was performed in treatments lasting 30 days for each patient.
  • the treatment was performed on an outpatient basis and there were two control visits per patient, one at the beginning of the treatment, with the delivery of the product under study, and, another at the end of the treatment, with the collection of data and opinions.
  • the final research product sulfur liposome element, was tested or tested in twelve voluntary patients of both sexes, between the ages of 16 and 24, affected by acne of varying severity.
  • the final research product has the same dosage and presentation described in the "presentation" section.
  • the clinical trial of the final research product was extended over a period of six months and 21-day treatments were performed on each patient.
  • the treatment was performed on an outpatient basis and there were two control visits per patient, one at the beginning of the treatment, with the delivery of the product, and, another at the end of the treatment, with the collection of data and opinions.
  • Between the second or third day of the beginning of treatment all patients could see an improvement in their general picture. To a greater or lesser degree, all patients noticed and reported a decrease in the amount of fat and skin luster, accompanied by a decrease in the inflammatory or erythematous component of comedones.
  • the product was very well tolerated by all patients, and, except for some dry skin that occurred in three of the cases, there were no allergic or other adverse reactions.
  • PEP Peptone Water
  • E.coli A (S-LIP 0.4) B (S-POL 0.4)
  • Positive control 2ml were dispensed. of physiological serum with each bacterial strains at the different concentrations, according to the following table:
  • Table 2 All tubes were mixed in vortex and incubated at 37 ° C for 48 hours. - 0.1 ml were inoculated. of each tube in an AN plate. - All plates were incubated at 37 ° C for 24 hours.
  • liposome sulfur has a bactericidal activity superior to that of powdered sulfur for all strains that have been tested (S. aureus, P.aeruginosa and E.coli), since in the test with the liposome form no growth was obtained at inoculum concentrations of up to 10 6 CFU in all cases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition comprenant une suspension de liposomes, lesquels contiennent du soufre incorporé dans leur membrane lipidique, ainsi que l'utilisation de ladite composition dans le traitement de maladies dermatologiques telles que la dermatite séborrhéique ou l'acné.
PCT/ES2015/070062 2014-01-29 2015-01-29 Composition de soufre liposomé Ceased WO2015114194A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201430103 2014-01-29
ES201430103A ES2542088B1 (es) 2014-01-29 2014-01-29 Composición de azufre liposomado

Publications (1)

Publication Number Publication Date
WO2015114194A1 true WO2015114194A1 (fr) 2015-08-06

Family

ID=52682754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2015/070062 Ceased WO2015114194A1 (fr) 2014-01-29 2015-01-29 Composition de soufre liposomé

Country Status (2)

Country Link
ES (1) ES2542088B1 (fr)
WO (1) WO2015114194A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207679A1 (en) * 2007-02-16 2008-08-28 Noah Berkowitz Glutathione peroxidase mimetics for the treatment of dermatoses
US7867480B1 (en) * 1999-01-27 2011-01-11 Gregor Cevc Non-invasive vaccination through the skin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079898A1 (fr) * 2006-12-20 2008-07-03 Pharmwest, Inc. Méthodes et formulations topiques comprenant un métal colloïdal servant à traiter ou prévenir des affections cutanées
MX2010013562A (es) * 2008-06-26 2011-02-15 Anterios Inc Aplicacion dermica.
US20100034873A1 (en) * 2008-08-06 2010-02-11 Delprete Keith Transdermal ricinoleic acid compositions
MX356518B (es) * 2009-04-24 2018-05-31 Iceutica Pty Ltd Producción de nanopartículas encapsuladas en fracciones de alto volumen.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867480B1 (en) * 1999-01-27 2011-01-11 Gregor Cevc Non-invasive vaccination through the skin
US20080207679A1 (en) * 2007-02-16 2008-08-28 Noah Berkowitz Glutathione peroxidase mimetics for the treatment of dermatoses

Also Published As

Publication number Publication date
ES2542088A1 (es) 2015-07-30
ES2542088B1 (es) 2016-05-05

Similar Documents

Publication Publication Date Title
CN106691889B (zh) 一种高皮肤滞留神经酰胺纳米组合物及其制备方法和用途
US20030170194A1 (en) Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid
Narshana et al. An overview of dandruff and novel formulations as a treatment strategy
CN101453985A (zh) 促进毛发生长的组合物
US11547665B2 (en) Multiphasic compositions
JP2016516765A5 (fr)
JP2009545587A (ja) エステル化レシチンを用いたナノリポソーム及びその製造方法、及びこれを含む皮膚疾患の予防又は治療用組成物
AU2012214662A1 (en) Permeation enhancers for topical formulations
JP2019006697A (ja) 活性酸素消去剤
JP2019006696A (ja) 活性酸素消去剤
JP2016044167A (ja) 外用組成物
MX2011013407A (es) Solucion oftálmica nanotecnológica a base de extractos herbolarios a partir de manzanilla y caléndula.
JP4989119B2 (ja) ベシクル系に好適な皮膚外用剤
US20120201871A1 (en) Permeation enhancers with liposomes for topical formulations
KR100785484B1 (ko) 고농도의 이데베논을 나노캡슐화한 기제 조성물, 이의제조방법 및 이를 함유한 화장료
ES2542088B1 (es) Composición de azufre liposomado
ES2379474T3 (es) Producto dermatológico para el tratamiento y/o cuidado de la piel con neurodermitis
JP6322575B2 (ja) 脂質マイクロカプセルのデリバリービヒクルを含む局所用製剤およびその使用
US9415054B2 (en) Piroxicam transdermal composition to treat plantar fasciitis
ES2345104T3 (es) Uso de liposomas de povidona yodada para el tratamiento de la dermatitis atopica.
CN104619311A (zh) 囊泡制剂、试剂盒和用途
Patel et al. AN INCLUSIVE review on novel drug delivery strategies for an effectual delivery of bio-active drug molecules in the treatment of acne
PT90134B (pt) Processo para a preparacao de composicoes farmaceuticas com propriedades de preservacao e restauracao da saude da pele
BR102023004857B1 (pt) Nanocarreadores lipídicos carregados com nitrosilo complexo de rutênio para o tratamento de leishmaniose
ES2608476B1 (es) Compuestos para el tratamiento de las enfermedades causadas por parásitos del género leishmania

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15709976

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15709976

Country of ref document: EP

Kind code of ref document: A1